HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.

AuthorsBente Glintborg, Stylianos Georgiadis, Anne Gitte Loft, Asta Linauskas, Hanne Lindegaard, Oliver Hendricks, Dorte V Jensen, Birgitte Lange Andersen, Kamilla Danebod, Anders Villumsen, Grith Eng, Charlotte Wiell, Natalia Manilo, Salome Kristensen, Johnny Raun, Jolanta Grydehøj, Stavros Chrysidis, Mette Nørgaard, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 79 Issue 6 Pg. 846-848 (06 2020) ISSN: 1468-2060 [Electronic] England
PMID32111583 (Publication Type: Letter, Observational Study)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biosimilar Pharmaceuticals
  • Etanercept
Topics
  • Adult
  • Aged
  • Ambulatory Care (statistics & numerical data)
  • Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
  • Arthritis (drug therapy)
  • Biliary Tract Diseases (epidemiology, etiology)
  • Biosimilar Pharmaceuticals (adverse effects)
  • Chemical and Drug Induced Liver Injury (epidemiology, etiology)
  • Cohort Studies
  • Denmark (epidemiology)
  • Etanercept (adverse effects)
  • Female
  • Hospitalization (statistics & numerical data)
  • Humans
  • Incidence
  • Male
  • Medical Record Linkage
  • Middle Aged
  • Registries

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: